Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 731-739

  Ngundi, Miriam M ^a   Meade, Bruce D ^b   Little, Stephen F ^c   Quinn, Conrad P ^d   Corbett, Cindi R ^e   Brady, Rebecca A ^a   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Meade Biologics   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIUM ANTIBODY; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F9; MONOCLONAL ANTIBODY AVR1046; MONOCLONAL ANTIBODY C3; MONOCLONAL ANTIBODY F20G75; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BACILLUS ANTHRACIS; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENTIATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; TOXIN ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; CELL LINE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS;

EID: 84860319425     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05714-11     Document Type: Article

References (42)

1. Abboud N, et al. 2010. A requirement for FcgammaR in antibodymediated bacterial toxin neutralization. J. Exp. Med. 207:2395-2405.
2. Baldari CT, Tonello F, Paccani SR, Montecucco C. 2006. Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol. 27:434-440. (Pubitemid 44216190)
3. Boyer AE, et al. 2007. Detection and quantification of anthrax lethal factor in serum by mass spectrometry. Anal. Chem. 79:8463-8470. (Pubitemid 350171353)
4. Brady RA, Verma A, Meade BD, Burns DL. 2010. Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays. Clin. Vaccine Immunol. 17:1390-1397.
5. Brossier F, Levy M, Landier A, Lafaye P, Mock M. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317. (Pubitemid 39425410)
6. Chen Z, et al. 2009. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect. Immun. 77:3902-3908.
7. Clement KH, et al. 2010. Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro. Clin. Vaccine Immunol. 17:1753-1762.
8. Collier RJ, Young JA. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70. (Pubitemid 37487342)
9. Cybulski RJ, Jr., Sanz P, O'Brien AD. 2009. Anthrax vaccination strategies. Mol. Aspects Med. 30:490-502.
10. Dang O, Navarro L, Anderson K, David M. 2004. Cutting edge: Anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J. Immunol. 172:747-751. (Pubitemid 38113728)
11. Duesbery NS, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737. (Pubitemid 28243347)
12. Ebrahimi CM, Sheen TR, Renken CW, Gottlieb RA, Doran KS. 2011. Contribution of lethal toxin and edema toxin to the pathogenesis of anthrax meningitis. Infect. Immun. 79:2510-2518.
13. Fellows PF, et al. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247. (Pubitemid 32324053)
14. Friedlander AM, Little SF. 2009. Advances in the development of nextgeneration anthrax vaccines. Vaccine 27:D28-D32.
15. Gubbins MJ, et al. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47:436-443. (Pubitemid 44035895)
16. Inglesby TV, et al. 1999. Anthrax as a biological weapon. JAMA 281: 1735-1745.
17. Leppla SH. 1982. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166. (Pubitemid 12008374)
18. Li H, et al. 2008. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J. Immunol. Methods 333:89-106.
19. Li Y, Sherer K, Cui X, Eichacker PQ. 2007. New insights into the pathogenesis and treatment of anthrax toxin-induced shock. Expert Opin. Biol. Ther. 7:843-854. (Pubitemid 46954431)
20. Little SF, Ivins BE, Fellows PF, Friedlander AM. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175. (Pubitemid 27513566)
21. Little SF, et al. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430. (Pubitemid 37510273)
22. Little SF, Leppla SH, Cora E. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
23. Little SF, et al. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142(Pt. 3):707-715. (Pubitemid 26093657)
24. Little SF, Webster WM, Fisher DE. 2011. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 62:11-22.
25. Loving CL, et al. 2009. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect. Immun. 77:255-265.
26. Maynard JA, et al. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20: 597-601. (Pubitemid 34595154)
27. Moayeri M, Leppla SH. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7:19-24. (Pubitemid 38223950)
28. Mohamed N, et al. 2004. Enhancement of anthrax lethal toxin cytotoxicity: A subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72:3276-3283. (Pubitemid 38697749)
29. Ngundi MM, Meade BD, Lin TL, Tang WJ, Burns DL. 2010. Comparison of three anthrax toxin neutralization assays. Clin. Vaccine Immunol. 17:895-903.
30. Nowakowski A, et al. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 99:11346-11350. (Pubitemid 34920928)
31. Pitt ML, et al. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773. (Pubitemid 32800762)
32. Quilliam AL, Osman N, McKenzie IF, Hogarth PM. 1993. Biochemical characterization of murine Fc gamma RI. Immunology 78:358-363.
33. Ravetch JV, et al. 1986. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 234:718-725. (Pubitemid 17184216)
34. Reason D, Liberato J, Sun J, Keitel W, Zhou J. 2009. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect. Immun. 77:2030-2035.
35. Reuveny S, et al. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893. (Pubitemid 32332179)
36. Rossi Paccani S, et al. 2007. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol. 9:924-929.
37. Subramanian GM, et al. 2005. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. 41:12-20. (Pubitemid 40863738)
38. Unkeless JC. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150:580-596. (Pubitemid 9250687)
39. Verma A, et al. 2009. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin. Vaccine Immunol. 16:1405-1412.
40. Vitale L, et al. 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccineinduced immunity. Infect. Immun. 74:5840-5847. (Pubitemid 44484571)
41. Weiss S, et al. 2006. Immunological correlates of protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74:394-398. (Pubitemid 43023096)
42. Welkos S, Little S, Friedlander A, Fritz D, Fellows P. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685. (Pubitemid 32544833)